Documents A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon:

A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07 N. Wolmark, S. Wieand, P. J. Kuebler,…

Documents MOSAIC

MOSAIC Stage ll+lll FOLFOX4 LV5FU2 Randomize DFS DFS (months) Hazard ratio: 0.77 [0.65 – 0.92] p < 0.01 FOLFOX (n=1123) 77.9% LV5FU2 (n=1123) 72.8% 23 % risk reduction…

Documents MOSAIC Stage ll+lll FOLFOX4 LV5FU2 Randomize. DFS DFS (months) Hazard ratio: 0.77 [0.65 – 0.92] p....

MOSAIC Stage ll+lll FOLFOX4 LV5FU2 Randomize DFS DFS (months) Hazard ratio: 0.77 [0.65 – 0.92] p < 0.01 FOLFOX (n=1123) 77.9% LV5FU2 (n=1123) 72.8% 23 % risk reduction…